• Management of type 2 diabetes (T2D) is balanced between achieving and maintaining target glycaemic control (haemoglobin A1c (HbA1c)) to avoid or delay the onset of costly macro-and microvascular complications, and avoiding hypoglycaemia. For new treatments addressing both components is critical in T2D management. • Over the recent years, several cardiovascular outcome trials (CVOTs) have been published with glucose lowering drugs. • In the EMPA-REG OUTCOME trial 1,2 , empagliflozin (SGLT2) + standard of care (SoC) was compared to SoC (placebo arm in the trial) in patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD). • The LEADER trial 3 for liraglutide (GLP1) was designed similarly i.e. in patients with T2D and established CVD.
CDM overview
• The IQVIA Core Diabetes Model (CDM) CVO v9.0, a well-established microsimulation model with 17 interdependent Markov sub-models was used to capture major complications (CV, renal, ophthalmological, nephropathy etc.) of diabetes along with management cost and results were generated for incremental costs, life expectancy (LE), and quality-adjusted life years (QALYs) • The model was calibrated to reproduce the 3-year event rates (recalculated from the event rates per 1000 patient years) from the EMPA-REG OUTCOME trial, for empagliflozin + SoC. • A Network Meta-Analysis (NMA) provided the relative risks for CVD outcomes with empagliflozin versus liraglutide 4 . The CDM was then calibrated to reproduce liraglutide trials' outcomes. • In Table 1 the results of the calibration are shown. 
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Analytic Overview
• The UK NHS perspective was taken, so only direct costs were considered. • Annual discounting of 3.5% was applied on costs and outcomes.
• The time horizon was 5 years.
• HbA1c progression for all arms was projected based on the progression in the EMPA-REG OUTCOME trial. • The effects of the CVOTs were applied for the full 5 years, no treatment switch was foreseen. • UK unit costs of complications and quality of life data were taken from literature. The drug costs were from the British National Formulary and Monthly Index of Medical Specialities with all the costs reported in 2015 British Pounds (GBP) • The analysis included patients from EMPA-REG OUTCOME trial with mean age 63 years and 71% male with 9 years of duration of diabetes and 8.07% HbA1c ( Table 2) • The treatment effect on physiological parameters was applied in the CDM in two ways:
✓ 1st year effect was programmed in the treatment settings together with the associated adverse event rates of each treatment (Table 3) ✓ For 2nd and 3rd years, the treatment effect followed the progression over time available in respective trials of empagliflozin and liraglutide, while from 4th year onwards, HbA1c progression from the empagliflozin was applied for all competitors To assess the short-term (5 years 
Base case Results
• In the base case analysis, empagliflozin showed additional LE and higher QALY at a lower cost resulting in dominance of empagliflozin compared to liraglutide (Table 4 ).
Table 4. Cost-effectiveness results
• At 5 years, empagliflozin has lower risk of CV and non-CV death as compared to liraglutide (Figure 1) .
• Empagliflozin has a lower projected incidence of heart failure, but angina, stroke and PVD incidence were higher ( Figure 2 ).
• Empagliflozin has lower total cost which was attributed to liraglutides higher treatment cost.
• Empagliflozin has higher cost of treating CVD complications, which was driven by the high cost of stroke management (Table 5 ). Probabilistic Sensitivity Analysis • The probabilistic sensitivity analyses performed on the base case demonstrated that Empagliflozin is costeffective vs. liraglutide in 81% of the simulations for a willingness to pay threshold of £20,000 per QALY, in which dominance is only observed in 69% of the simulations reports (Figure 3 and 4) .
The cost-effectiveness analyses based on the results of the EMPA-REG OUTCOME and LEADER trials, demonstrate that empagliflozin + SoC is dominant compared to Liraglutide + SoC from the UK NHS perspective. 
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